SBRT prostate after prior EBRT?

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

thesauce

Senior Member
15+ Year Member
Joined
Aug 5, 2005
Messages
3,825
Reaction score
1,549
Has anyone done SBRT after prior EBRT or brachy? I found 2 relatively recent studies and it seems to be equally-effective and better tolerated than some other modalities out there. Thoughts?



Members don't see this ad.
 
I do it all the time. I use Dr. Fuller's protocol published in PRO.

 
Has anyone done SBRT after prior EBRT or brachy? I found 2 relatively recent studies and it seems to be equally-effective and better tolerated than some other modalities out there. Thoughts?


Unless they have had prior LDR brachy, I typically prefer HDR for in-gland salvage. There is a pretty good literature for it. I have yet to see a major complication or even severe LUTs. The literature on salvage SBRT is mixed but I know folks (apparently GFunk is one of them) who do it and it seems to go ok as well.
 
Members don't see this ad :)
Yes, our practice does. I personally have not done it for in-gland recurrences less than 4 years after previous EBRT. I do try to get a perirectal spacer in before re-RT, but optimal spacer placement is not as high as in the RT-naive setting given fibrosis/scarring in that space. It does take a fair amount more dissection and gentle manipulation to create the pocket. We've used 35-36.25/5fx.
 
I've done it after HDR which was done more than 10 years ago. It was scary to do, but the patient has done well.
 
I haven't done this.

Excuse my ignorance.

Do you all do just focal radiation based upon biopsy location/MRI (and now PSMA or axumin)? LIke gross disease plus (small) margin?

Of note, on quick glance at the Fuller paper they only included patients with G1 toxicity at XRT round 1 only. So clearly you need to be selective.
 
I treat whole gland but dose escalate to gross disease

I think that's what I would probably do too in my theoretical world.

But a congruent saturation biopsy, MRI, and now with PSMA pet would be really tempting to just treat a hot area.
 
I think that's what I would probably do too in my theoretical world.

But a congruent saturation biopsy, MRI, and now with PSMA pet would be really tempting to just treat a hot area.
I see where you are coming from but the counter argument is you only get one shot at this. I’ve re-treated the whole gland with HDR 30/3 (albeit in folks with good baseline urinary function) a few times without any notable toxicity. In the definitive setting, hemi-gland BT failed miserably even with pretty thorough work up. Until I see good data otherwise, I feel like if you are going to do it, do it right.
 
36.25 / 5 fractions; checking every day that no hot spot in urethra (max dose 38.8) as well as the prostate/rectal boundary is appropriate. Some patients have had fluciclovine PET, only a few with PSMA-PET due to availability where we are. We may have done between 5 and 10 cases thus far. Since we have MR guidance, we have been using that. Not enough for a series yet.
 
On a slightly different but related note, I have also used 45/30 BID as an aggressive palliation dose for folks with symptomatic in gland recurrences after full dose in guys who also have Mets and been extremely happy with it. First guy I did it in was close to needing a suprapubic cath. Told him I might make things better or worse and ended up getting him 2.5 years of complete resolution of his LUTS. Oddly enough, it helped with his castrate resistance too. I eventually ended up treating his PA nodes with a modest dose and he’s still doing great on ADT (though PSA is starting to rise slowly again even on ADT…but still, happy to buy a couple more years). No toxicity issues. I’ve also used this dose a couple times for secondary rectal cancers after bladder or prostate RT in medically inoperable folks a few times. Not enough for a series but something that has served me well.
 
36.25 / 5 fractions; checking every day that no hot spot in urethra (max dose 38.8) as well as the prostate/rectal boundary is appropriate. Some patients have had fluciclovine PET, only a few with PSMA-PET due to availability where we are. We may have done between 5 and 10 cases thus far. Since we have MR guidance, we have been using that. Not enough for a series yet.

Putting spacer in?
 
Members don't see this ad :)
Not sure if prior radiation affects denonvilliers fascia? Edit: just checked it seems to be a relative contraindication
I just put in a SpaceOAR on a patient with locally recurrent prostate cancer s/p IMRT (78 Gy) delivered about 7 years ago. Axumin PET confirmed local recurrence without regional or metastatic disease.

Both the prostate and denonvilliers fascia were notably fibrotic based on the tactile feel with the needles. However, the fascia in particular appeared normal (like fat) on TRUS.
 
Putting spacer in?
Yes, definitely try to place SpaceOAR. I have performed a few and I will usually encounter some fibrosis of the Denonvilliers Fascia. Most will open up with hydrodissection to allow adequate placement of the gel, but some are totally stuck. It those situations, I may decide to go partial prostate vs whole gland, depending on disease location/size and pt's baseline GI/urinary status. Salvage brachy, HIFU, Cryo can be considered if you have the expertise locally...
 
Reviving old thread but mostly appropriate as it fits the general idea of RT after RT. Seeing a guy s/p HDR brachy 10 yrs ago for LR prostate. Now with BCR and PSMA PET avid nodule in the back of 1 lobe pending biopsy. Wondering about options from EBRT perspective, etc. One rec to me was repeat HDR. From an EBRT perspective SBRT seems feasible, but mod hypo or conventional perhaps safer. I would think biggest risk is urethral tox as opposed to rectal. Moderate dose to prostate and boost nodule/spare urethra etc. other local ablative options with Urology?
 
Looks like similar to the OP case in that the progression is at the base of and into the SV. I suspect I could safely SBRT the spot plus margin while entirely missing urethra and minimally dosing the rectum. I can't find much precedent for nodule only SBRT in lit, though frequently for nodule only HDR. Doing things kind of in reverse, but wondering if there's a go-to paper. Other option is nodule only re-HDR.
 
I've done SBRT before in the setting of prior EBRT. There's decent data. Agree with biopsy first.
Whole prostate or nodule plus margin? My case is in the context of prior HDR. Perhaps no diff on some level, but just looking for a pub re both of these things: treatment of lesion plus margin only, and EBRT after HDR.
 
Reviving old thread but mostly appropriate as it fits the general idea of RT after RT. Seeing a guy s/p HDR brachy 10 yrs ago for LR prostate. Now with BCR and PSMA PET avid nodule in the back of 1 lobe pending biopsy. Wondering about options from EBRT perspective, etc. One rec to me was repeat HDR. From an EBRT perspective SBRT seems feasible, but mod hypo or conventional perhaps safer. I would think biggest risk is urethral tox as opposed to rectal. Moderate dose to prostate and boost nodule/spare urethra etc. other local ablative options with Urology?
I would get an MRI as well. Full sextant biopsy as well as ROI biopsy. If ONLY site of pCA is the PET avid area, I would be open to nodule + margin. However, full prostate biopsy necessary to ensure you don't need to treat the entire prostate. If anything beyond the PSMA PET avid nodule pops up as pCA, re-treat entirety of gland (can consider FLAME-style boost to PET avid lesion as feasible)

I only re-treat with SBRT because that's where the bulk of atleast conempotrayr data stands. Need to monitor for both rectal and urethral toxicity but there aren't really any well validated dose constraints for toxicity. Most folks seem to do OK though.

A non-RT alternative would be if its limited to the prostate would be to consider cryo per MASTER meta-analysis, some places are also offering HIFU although MASTER was not very positive on toxicity from that.
 
Salvage prostatectomy to me seems reasonable if pts are young etc
Wrong per MASTER Meta-anslysis.

So, what dose of SBRT would you all give?
36.25Gy to PTV, 40Gy to CTV. Same 'constraints' as initial plan but treating all the quite conservative soft constraints on an initial 5fx SBRT plan like hard constraints, especially for rectum and bladder. Generally recommend a Barrigel in this space especially if nodule is posteriorly located. Don't love SpaceOAR in previously irradiated tissue.
 
I’ve been doing this for the better part of 5 years with SBRT or HDR and in my experience, nodule plus margin isn’t enough and I only do it for people with significant obstructive symptoms. I had too many subsequent in gland failures. I get (or got) PYL, MRI, and sat biopsy for everyone. It’s no different than the upfront setting…there is often more than you can see. I treat whole prostate to 37.5 and decrease BR001 constraints by 20% keeping full coverage to the module and coverage of the whole gland to at least 85%. Plans come out hot but if you manage the urethral dose, it goes fine.

One exception are the LDR patients with failures in the base with no seeds in the base. It’s not great mystery why those failed and I tend to be more focused.
 
I’ve been doing this for the better part of 5 years with SBRT or HDR and in my experience, nodule plus margin isn’t enough and I only do it for people with significant obstructive symptoms. I had too many subsequent in gland failures. I get (or got) PYL, MRI, and sat biopsy for everyone. It’s no different than the upfront setting…there is often more than you can see. I treat whole prostate to 37.5 and decrease BR001 constraints by 20% keeping full coverage to the module and coverage of the whole gland to at least 85%. Plans come out hot but if you manage the urethral dose, it goes fine.

One exception are the LDR patients with failures in the base with no seeds in the base. It’s not great mystery why those failed and I tend to be more focused.
Fwiw, I'd argue the case I'm seeing is similar to the last example. It's a failure vs new primary in base of SV, which was likely underdosed vs missed during primary HDR. Is this more of a focused situation for you. It's def not an in-field failure. At margins vs outside.
 
Fwiw, I'd argue the case I'm seeing is similar to the last example. It's a failure vs new primary in base of SV, which was likely underdosed vs missed during primary HDR. Is this more of a focused situation for you. It's def not an in-field failure. At margins vs outside.
I agree. That sounds like exactly the situation I described as well and keeping it focused makes sense. I’ve only had 1 in gland failure I know of after HDR and it was exactly where you described. I did focal SBRT about a year ago and so far, so good.

I was speaking more generally. Most of the referrals I get are square in the PZ and should definitely have been treated previously.
 
Top